Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Alligator Bioscience

Drug Profile

Research programme: cancer therapeutics - Alligator Bioscience

Alternative Names: ADC-1001; ADC-1001-RA; ADC-1004; ADC-1004-CHIPS; ADC-1012; ADC-1014; ADC-1015; ADC-CHIPS; ATOR 1015; ATOR 1017; Bispecific antibodies for cancer indications - Alligator Bioscience; FIND-1001; FIND-1004; TNFR-SF + ND - bispecific antibody; TNFR-SF - monospecific antibody

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alligator Bioscience
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antirheumatics; Bispecific antibodies; Monoclonal antibodies; Proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Complement C5a inhibitors; Immunomodulators; Immunostimulants; Interleukin 1 receptor antagonists; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammation

Highest Development Phases

  • Preclinical Cancer; Solid tumours
  • No development reported Diabetes mellitus; Gout; Inflammation; Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Discontinued Reperfusion injury

Most Recent Events

  • 05 Oct 2018 Alligator Bioscience plans a clinical trial in Cancer in 2019
  • 04 Sep 2018 Preclinical development of ATOR 1015 is ongoing in Solid tumours in Sweden
  • 04 Sep 2018 Preclinical trials in Cancer in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top